Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

References

• Andersson K-E, Appell R, Awad S, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Khoury S, Wein A, editors. Incontinence, 2nd international consultation on incontinence. Plymouth: Plymbridge Distributors Ltd; 2002. p. 480–511
   Google Scholar
• Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol 2001;19:299–306
   Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001;87:760–6 [erratum 2001;88: 807]
   Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327–36
   PubMed Web of Science ®Google Scholar
• Haferkamp A, Elbadawi A. Ultrastructural changes in the aging bladder. Urologe A 2004;43:527–34 [German]
   Google Scholar
• Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992;149:1393–4
   PubMed Web of Science ®Google Scholar
• Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging 2005;22:1013–28
   PubMed Web of Science ®Google Scholar
• Andersson K-E. Potential benefits of muscarinic M3 receptor selectivity. Eur Urol Suppl 2002;1:23–8
   Web of Science ®Google Scholar
• Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005;48:471–7
   PubMed Web of Science ®Google Scholar
• Malone-Lee JG, Walsh JB, Maugourd M-F, et al. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700–5
   Google Scholar
• Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002;50:799–807
   Google Scholar
• Zorzitto ML, Holliday PJ, Jewett MAS, et al. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 1989;18:195–200
   PubMed Web of Science ®Google Scholar
• Szonyi G, Collas Dm, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995;24:287–91
   PubMed Web of Science ®Google Scholar
• Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14–24
   Google Scholar
• Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001;18:551–60
   PubMed Web of Science ®Google Scholar
• Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 2002;34:43–9
   PubMedGoogle Scholar
• Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588–95
   Google Scholar
• Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20:392–9
   PubMed Web of Science ®Google Scholar
• Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. Br J Urol Int 2006;98:1025–32
   Google Scholar
• Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45: 420–9
   Google Scholar
• Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3 selective receptor antagonist. Br J Urol Int 2005;95:580–6 [erratum 2005;95: 1385–6]
   Google Scholar
• Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311–5
   PubMed Web of Science ®Google Scholar
• Szonyi G, Collas DM, Ding YY, Malone-Lee JG. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995;24:287–91
   Google Scholar
• Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700–5
   Google Scholar
• Haab F, Cardozo L, Chapple C, Ridder AM; Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376–84
   Google Scholar
• Salvatore S, Khullar V, Cardozo L, et al. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol 2005;119:237–41
   PubMed Web of Science ®Google Scholar
• Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000;20:470–5
   PubMed Web of Science ®Google Scholar
• Ouslander JG, Shih YT, Malone-Lee J, Luber K. Overactive bladder: special considerations in the geriatric population. Am J Manag Care 2000;6(Suppl 11):S599–S606
   Google Scholar
• Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype [abstract]. As presented at the International Continence Society 2002, Heidelberg, Germany as a non-discussion poster abstract. A445. Available at http://www.icsoffice.org/publications/2002/PDF/445.PDF [last accessed 24 May 2007]
   Google Scholar
• Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005;45:1038–47
   PubMed Web of Science ®Google Scholar
• Kay GG, Abou-Donia MB, Messer Jr WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005;53:2195–201
   PubMed Web of Science ®Google Scholar
• Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50:317–26
   PubMed Web of Science ®Google Scholar
• Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005;173:493–8
   Google Scholar
• Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565–78
   PubMed Web of Science ®Google Scholar